Nova Mentis Life Science Corp. has formed a tactical partnership with KGK Science Inc. to develop its psilocybin drug portfolio in Canada. Both Companies plan to jointly submit the Health Canada clinical trial application.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | 0.00% | 0.00% | -25.00% |
1st Jan change | Capi. | |
---|---|---|
-25.00% | 16.26L | |
+29.03% | 4.82TCr | |
-0.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+11.48% | 2.56TCr | |
-22.74% | 1.9TCr | |
+9.06% | 1.29TCr | |
+30.01% | 1.2TCr | |
-1.51% | 1.18TCr |
- Stock Market
- Equities
- NOVA Stock
- News Nova Mentis Life Science Corp.
- Nova Mentis Life Science Corp. Forms A Tactical Partnership with KGK Science Inc. to Develop Its Psilocybin Drug Portfolio in Canada